These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 22036246)
1. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study. Farcasiu E; Ivanyi T; Mozejko-Pastewka B; Birkus Z; Csog J; Kowalska I; Coetzer TF; Bulgurlu S; Schinzel B; Kiljanski J Clin Ther; 2011 Nov; 33(11):1682-93. PubMed ID: 22036246 [TBL] [Abstract][Full Text] [Related]
2. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076 [TBL] [Abstract][Full Text] [Related]
3. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia. Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078 [TBL] [Abstract][Full Text] [Related]
4. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497 [TBL] [Abstract][Full Text] [Related]
5. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Ilag LL; Kerr L; Malone JK; Tan MH Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388 [TBL] [Abstract][Full Text] [Related]
6. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH; Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767 [TBL] [Abstract][Full Text] [Related]
7. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414 [TBL] [Abstract][Full Text] [Related]
8. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G; Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747 [TBL] [Abstract][Full Text] [Related]
9. Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial. Watada H; Imori M; Li P; Iwamoto N Endocr J; 2017 Jul; 64(7):705-717. PubMed ID: 28539526 [TBL] [Abstract][Full Text] [Related]
10. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500 [TBL] [Abstract][Full Text] [Related]
11. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883 [TBL] [Abstract][Full Text] [Related]
12. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as an insulin starter in Asian patients with type 2 diabetes: a phase 4, open-label, randomized trial (CLASSIFY study). Watada H; Su Q; Li PF; Iwamoto N; Qian L; Yang WY Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155890 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038 [TBL] [Abstract][Full Text] [Related]
14. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Hollander P; Cooper J; Bregnhøj J; Pedersen CB Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs. Yang W; Ersoy C; Wang G; Ye S; Liu J; Miao H; Asirvatham A; Werther S; Kadu P; Chow F Diabetes Res Clin Pract; 2019 Apr; 150():158-166. PubMed ID: 30872064 [TBL] [Abstract][Full Text] [Related]
16. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Buse JB; Wolffenbuttel BH; Herman WH; Shemonsky NK; Jiang HH; Fahrbach JL; Scism-Bacon JL; Martin SA Diabetes Care; 2009 Jun; 32(6):1007-13. PubMed ID: 19336625 [TBL] [Abstract][Full Text] [Related]
17. Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial. Jin SM; Kim JH; Min KW; Lee JH; Ahn KJ; Park JH; Jang HC; Park SW; Lee KW; Won KC; Kim YI; Chung CH; Park TS; Lee JH; Lee MK J Diabetes; 2016 May; 8(3):405-13. PubMed ID: 25952532 [TBL] [Abstract][Full Text] [Related]
18. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750 [TBL] [Abstract][Full Text] [Related]
19. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes. Jovanovič L; Peters AL; Jiang HH; Hardin DS Aging Clin Exp Res; 2014 Apr; 26(2):115-21. PubMed ID: 24092662 [TBL] [Abstract][Full Text] [Related]
20. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]